Seeing a return on investment in pharma marketing means understanding what happens to every dollar.
Those challengers who address critical patient needs beyond traditional treatment will become a force to be reckoned with.
Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.
In this episode of the Oliver Wyman Health Podcast, we share what it's like to be the only female leader in the room, and discuss how digital innovation is advancing social determinants of health.
Natural language processing is the perfect example of how AI can maximize people's talents, impact, and value. But its potential is just being realized.
Tomorrow's value will be unlocked once parties synergize incentives.
How pharmaceutical companies can better define, measure, and deliver value to patients.
Edelman's solution-based advice on regaining trust in healthcare and how it got lost in the first place.
We reviewed the approaches State legislators took to offset the effect of defunding CSRs. Here are our observations of activity across the country.